Welcome to our dedicated page for Rapport Therapeutics SEC filings (Ticker: RAPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
Rapport Therapeutics, Inc. Chief Operating Officer Cheryl Gault reported selling a total of 10,000 shares of Common Stock in open-market transactions. She sold 7,161 shares at a weighted average price of $28.0401 and 2,839 shares at a weighted average price of $28.5530. After these sales, she directly holds 159,914 shares. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating the sales were scheduled in advance rather than timed discretionarily.
RAPP submitted a Rule 144 notice listing a proposed sale of 10,000 shares of Common stock. The filing shows a value of $278,400.00 and references Cheryl Gault with an address on the filing. Dates shown include 09/05/2024 and 03/30/2026.
Rapport Therapeutics, Inc. Chief Development Officer Yeleswaram Krishnaswamy sold 10,115 shares of common stock in an open-market transaction at a weighted average price of $29.9906 per share. The shares were sold in multiple trades between $29.90 and $30.18.
After this sale, Krishnaswamy directly holds 286,876 shares of Rapport Therapeutics common stock. The transaction was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating the sale was scheduled in advance.
RAPP filed a Form 144 reporting proposed resale activity in its Common Stock. The filing lists an offering date of 05/20/2025 and a filing marker of 03/25/2026. The excerpt shows a reported sale of 2,840 Common shares on 12/31/2025 for $85,342.
Rapport Therapeutics, Inc. registered up to $150,000,000 of common stock for sale pursuant to an at-the-market sales agreement to be used on a shelf registration, to be sold from time to time after effectiveness.
The prospectus covers issuances of common stock, preferred stock, debt securities, warrants and units; the shelf replaces a prior Form S-3 that will terminate on July 7, 2028. As of March 6, 2026, there were 47,799,985 shares of common stock outstanding and the closing price was $30.24 per share on The Nasdaq Global Market under the symbol RAPP.
Rapport Therapeutics filed its annual report describing a precision neuroscience pipeline built on receptor associated protein (RAP) biology. The company had 47,792,943 common shares outstanding as of March 2, 2026, and non-affiliate equity market value of $275,840,930 as of June 30, 2025.
Lead candidate RAP-219, a TARPγ8‑targeted AMPA receptor modulator, showed positive Phase 2a proof‑of‑concept results in drug‑resistant focal onset seizures, with 85.2% of patients achieving at least a 30% reduction in intracranial long episodes and 72.0% achieving at least a 50% reduction in clinical seizures over eight weeks.
The report outlines plans for two global Phase 3 trials in focal onset seizures starting in the second quarter of 2026, further development in primary generalized tonic‑clonic seizures and bipolar mania, a long‑acting injectable formulation, and α6β4 and α9α10 nicotinic acetylcholine receptor programs for chronic pain, migraine, and hearing or vestibular disorders.
Rapport Therapeutics reported larger losses for the fourth quarter and full year 2025 as it ramped investment in its precision neuroscience pipeline. Quarterly net loss was $33.8 million versus $20.0 million a year earlier, and full-year net loss rose to $111.5 million from $78.3 million, driven mainly by higher R&D spending.
R&D expenses reached $94.8 million in 2025, up from $60.9 million, while G&A expenses increased to $30.3 million from $22.1 million. The company ended 2025 with $490.5 million in cash, cash equivalents, and short-term investments and expects this to fund operations into the second half of 2029.
Lead candidate RAP‑219 showed strong Phase 2a results in focal onset seizures, with a 77.8% median seizure reduction, 72% of patients achieving at least 50% reduction, and 24% achieving seizure freedom over eight weeks. Rapport plans to start a Phase 3 program in focal onset seizures in the second quarter of 2026 and expand into primary generalized tonic‑clonic seizures with a Phase 3 trial in 2027.
The company also advanced a Phase 2 trial in bipolar mania, long-acting injectable development, and an α6β4 chronic pain program. A new collaboration with Tenacia Biotechnology grants Tenacia rights to RAP‑219 in Greater China, with Rapport eligible for a $20 million upfront payment, up to $308 million in potential milestones and other payments, and tiered royalties.
Rapport Therapeutics, Inc. Chief Operating Officer Cheryl Gault reported an open-market sale of 2,014 shares of common stock at a weighted average price of $28.93 per share. According to the filing, the shares were sold solely to satisfy taxes from the vesting of a previously granted restricted stock unit award and did not represent a discretionary trade. After this transaction, she directly holds 169,914 shares of common stock. The sales occurred in multiple trades at prices ranging from $28.34 to $28.94.
Morgan Stanley Smith Barney LLC filed a Form 144 reporting proposed sale of restricted stock units that vested under a registered compensation plan. The filing lists the securities as Common and the relevant date is 03/03/2026; the brokerage location shows New York, NY. The notice is for sale activity under Section 144 procedures.
Rapport Therapeutics Chief Executive Officer Abraham Ceesay reported open-market sales of a total of 10,916 shares of common stock on February 18 under pre-arranged Rule 10b5-1 trading plans. He sold 5,833 shares held directly, at weighted average prices of $29.0516 and $29.7983 per share. An additional 5,083 shares were sold by The Dorothy Ceesay Irrevocable Trust, also at weighted average prices around $29 per share, with Ceesay disclaiming beneficial ownership except for any pecuniary interest. After these transactions, he holds 556,247 shares directly, while trusts associated with him hold 20,729 and 81,729 shares, respectively.